ClinicalTrials.gg
CompletedNCT00653614Updated Apr 23, 2015

Cycle Control and Safety of E2-DRSP

A Phase 2 interventional study of E2/DRSP (BAY 86-4891) dose 1 (SH T04984E) and E2/DRSP (BAY 86-4891) dose 2 (80458739) in Contraceptive, Oral, Hormonal, sponsored by Bayer. Completed at 25 sites in Germany. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2015-04-23.

Sponsored by Bayer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
635
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The study will be performed as a multi-center, randomized, double-blind, parallel-group trial in fertile women aged between 18 and 35 years inclusive. A total of 600 volunteers will be randomized into one of the six treatment groups. The study will be performed only in Germany. The investigational drug is an oral contraceptive. It contains the estrogen estradiol (E2) and the progestogen drospirenone (DRSP). As the contraceptive efficacy has not yet been proven for these new regimens, even a protection against unwanted pregnancies cannot be assured. The treatments will be applied daily for 7 cycles of 28 days each without pill-free interval, i.e., for 196 consecutive days. Treatment will be initiated after a screening period of approximately 1 to 2 weeks, the latter focused on confirmation of the baseline safety status. Tablet intake will start on the first day of the first menstrual/withdrawal bleeding after Visit 2, regardless of whether the volunteer is a first user (starter) or switching from another COC. In the following cycles, tablet intake is not to be triggered by any bleeding events. The primary objective of this study is to evaluate and compare the cycle control and bleeding patterns of six different treatment regimens with E2/DRSP during administration for 7 treatment cycles. Volunteers will be provided with a diary to document the intake of study medication, any bleeding events, and days without bleeding, pregnancy test results. Safety will be also assessed. During the whole study period, 4 visits are planned. At Screening and Final examination, a thorough physical examination and a gynecological examination (including breast palpation and cervical smear ) will be performed. Blood samples will be taken for safety laboratory parameters.Additional examinations can be performed any time, if this becomes necessary for medical reasons. At Visit 3 or in case of premature discontinuation of study the investigator will discuss options for follow-up contraception with the volunteer. The volunteer can start the intake of a post-treatment OC on the day after the last tablet intake of study medication, after a negative urine ß-HCG test (home pregnancy test) result.

02

Conditions studied

  • Contraceptive, Oral, Hormonal

Keywords

  • Oral contraception
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female volunteers
  • Age: 18 - 35 years (inclusive), smokers must not be older than 30 years at inclusion
  • History of regular cyclic menstrual periods (with a cycle length between 25 and 35 days)
  • Willingness to use barrier methods of (condoms with spermicide, diaphragms with spermicide, spermicidal vaginal suppositories) or abstinence during the trial

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, lactation (less than three menstrual cycles before Visit 1 following delivery, abortion, or lactation) - Obesity ( > 30.0 kg/m2)
  • Abnormal, suspicious or unclear cervical smear (a cervical smear has to be taken at Visit 1 or a normal result has to be documented within the last 6 months before Visit 1)
  • Laboratory values outside inclusion range at Screening - Any disease that may worsen under hormonal treatment or might interfere with the conduct of the study or the interpretation of the results, as e.g.: - Cardiovascular -- presence or a history of venous or arterial thrombotic/thromboembolic events (e.g., deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident, including prodromi (e.g., , angina pectoris) and conditions which could increase the risk to suffer from any of the above mentioned disorders, e.g., a family history indicating a hereditary predisposition. -- uncontrolled arterial hypertension (repeated measurements of systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg)
  • Liver -- presence or history of liver tumor (benign or malignant) -- presence or history of severe hepatic disease as long as liver function values have not returned to normal -- jaundice and/or pruritus related to cholestasis -- history of cholestatic jaundice associated with pregnancy or previous COC use
  • Metabolic diseases -- uncontrolled diabetes mellitus with vascular involvement severe dyslipoproteinemia
  • Other diseases: any known or suspected malignant or premalignant disease, uncontrolled thyroid disorder, chronic inflammatory bowel disease, severe renal insufficiency or acute renal failure, hemolytic uremic syndrome, sickle cell anemia, porphyria, history of hypertriglyceridemia-associated Pancreatitis, systemic lupus erythematodes, pemphigoid gestationis during a previous pregnancy, Sydenham chorea, herpes gestationis, otosclerosis-related hearing loss, history of migraine with focal neurologic symptoms, epilepsy, current or history of depression, hereditary angioedema
  • Additional sex , other hormonal methods (oral, transdermal) during treatment (blister in use at randomization should be finished); intra-uterine devices (IUD) with or without hormone release within 1 month prior to Visit 1, implants within 1 month prior Visit 1, depot progestins within 6 months prior to Visit 1 - Surgical interventions scheduled in the study period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
635 participants (actual)

Study arms

  • Experimental
    Arm 1

    E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle

    Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E) · Drug: DRSP (ZK 30595) dose 1 (SH T04984F) · Drug: Placebo

  • Experimental
    Arm 2

    E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle

    Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E) · Drug: DRSP (ZK 30595) dose 1 (SH T04984F) · Drug: Placebo

  • Experimental
    Arm 3

    E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle

    Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E) · Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739) · Drug: E2/DRSP (BAY 86-4891) dose 3 (80458755) · Drug: Placebo

  • Experimental
    Arm 4

    E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle

    Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E) · Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739) · Drug: E2/DRSP (BAY 86-4891) dose 3 (80458755) · Drug: E2/DRSP (BAY 86-4891) dose 4 (80458720) · Drug: DRSP (ZK 30595) dose 1 (SH T04984F) · Drug: Placebo

  • Experimental
    Arm 5

    E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle

    Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739) · Drug: E2/DRSP (BAY 86-4891) dose 5 (80458712) · Drug: Placebo

  • Experimental
    Arm 6

    E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle

    Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739) · Drug: E2/DRSP (BAY 86-4891) dose 4 (80458720) · Drug: E2/DRSP (BAY 86-4891) dose 5 (80458712) · Drug: DRSP (ZK 30595) dose 2 (80458690) · Drug: Placebo

Interventions

  • DrugE2/DRSP (BAY 86-4891) dose 1 (SH T04984E)

    Single dose administration of E2 + DRSP as a tablet

  • DrugE2/DRSP (BAY 86-4891) dose 2 (80458739)

    Single dose administration of E2 + DRSP as a tablet

  • DrugE2/DRSP (BAY 86-4891) dose 3 (80458755)

    Single dose administration of E2 + DRSP as a tablet

  • DrugE2/DRSP (BAY 86-4891) dose 4 (80458720)

    Single dose administration of E2 + DRSP as a tablet

  • DrugE2/DRSP (BAY 86-4891) dose 5 (80458712)

    Single dose administration of E2 + DRSP as a tablet

  • Single dose administration of DRSP as a tablet

  • Single dose administration of DRSP as a tablet

  • DrugPlacebo

    Placebo administration in each arm

06

What researchers measure

Primary outcomes

  1. Number of intracyclic bleeding episodes during cycles 2 to 7

    Time frame: 168 days

Secondary outcomes

  1. Number of intracyclic bleeding days (including spotting) in Cycles 2 to 7

    Time frame: 168 days

  2. Number of withdrawal bleeding episodes in Cycles 1 to 6

    Time frame: 168 days

  3. Bleeding pattern

    Bleeding pattern was determined by: - Number of bleeding/spotting days - Number of bleeding days (excluding spotting) - Number of spotting-only days - Number, mean length, maximum length, and range of length of bleeding/spotting episodes - Number, mean length, maximum length, and range of length of spotting-only episodes

    Time frame: Approximately 7 months

  4. Cycle control

    Withdrawal bleeding - Number of volunteers with/without withdrawal bleeding; - Length, maximum intensity, and onset of withdrawal bleeding episodes Intracyclic bleeding (including/excluding spotting) - Number of volunteers with/without intracyclic bleeding; - Number, maximum length, maximum intensity (including spotting only) of intracyclic bleeding episodes - Number of intracyclic bleeding days - Number of volunteers with at least one intracyclic bleeding (including/excluding spotting) episode in Cycles 2 - 6 and in Cycles 2 - 7

    Time frame: Approximately 7 months

  5. Subjective assessment of treatment

    The treatment satisfaction assessment was done through a questionaire. The investigator handed it over to the subject and the subject was asked to answer all questions by herself.

    Time frame: Day 196 - Day 210

  6. Number of participants with adverse events

    Time frame: Approximately 7 months

07

Study locations

25 sites
  • Krumbach, Bayern 86381, Germany
  • Nürnberg, Bayern 90491, Germany
  • Dietzenbach, Hessen 63128, Germany
  • Frankfurt, Hessen 60322, Germany
  • Frankfurt, Hessen 65936, Germany
  • Fulda, Hessen 36037, Germany
  • Mühlheim, Hessen 63165, Germany
  • Blankenburg, Sachsen-Anhalt 38889, Germany
  • Burg, Sachsen-Anhalt 39288, Germany
  • Jessen, Sachsen-Anhalt 06917, Germany
  • Magdeburg, Sachsen-Anhalt 39104, Germany
  • Magdeburg, Sachsen-Anhalt 39126, Germany
  • Dippoldiswalde, Sachsen 01744, Germany
  • Dresden, Sachsen 01099, Germany
  • Dresden, Sachsen 01169, Germany
  • Leipzig, Sachsen 04207, Germany
  • Leipzig, Sachsen 04299, Germany
  • Wurzen, Sachsen 04808, Germany
  • Gera, Thüringen 07545, Germany
  • Berlin, 10247, Germany
  • Berlin, 12587, Germany
  • Berlin, 13086, Germany
  • Berlin, 13507, Germany
  • Hamburg, 21073, Germany
  • Hamburg, 22159, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2008
First posted
Apr 7, 2008
Start
Mar 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Last update
Apr 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00653614
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 7, 2008
Start date
Mar 2008
Primary completion
Jun 2009
Completion
Jun 2009
Last update
Apr 23, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drospirenone

Start the discussion